Core Viewpoint - Dize Pharmaceutical announced a share reduction plan by senior management due to personal financial needs related to tax payments for equity incentives, with specific share amounts and percentages outlined for each individual involved [1][2]. Group 1: Share Reduction Details - Yang Zhenfan plans to reduce up to 1,154,000 shares, accounting for 0.2512% of the total share capital [1]. - Chen Suqin intends to reduce up to 129,000 shares, representing 0.0281% of the total share capital [1]. - Qingbei Zeng and Honchung Tsui each plan to reduce up to 85,000 shares, each accounting for 0.0185% of the total share capital [1]. - Lv Hongbin plans to reduce up to 19,000 shares, which is 0.0041% of the total share capital [1]. - The reduction period is from July 18, 2025, to October 17, 2025, with prices determined by market conditions during this period [1]. Group 2: Implementation Results - As of July 23, 2025, the share reduction has been completed, with the following results: Yang Zhenfan reduced 1,154,000 shares (0.2512%), Chen Suqin reduced 129,000 shares (0.0281%), Qingbei Zeng reduced 85,000 shares (0.0185%), Honchung Tsui reduced 85,000 shares (0.0185%), and Lv Hongbin reduced 19,000 shares (0.0041%) [2]. - Dize Pharmaceutical's revenue composition for 2024 is entirely from the pharmaceutical manufacturing sector, accounting for 100.0% [2]. Group 3: Market Capitalization - As of the latest report, Dize Pharmaceutical has a market capitalization of 32.2 billion yuan [3].

证券代码：688192 证券简称：迪哲医药 公告编号：2025-48 迪哲（江苏）医药股份有限公司 关于高级管理人员减持股份结果公告 高级管理人员持股的基本情况 本次股份减持计划实施前，迪哲（江苏）医药股份有限公司（以下简称"公 司"）首席医学官、副总经理杨振帆女士直接持有公司股份 4,616,750 股，占公司 总股本的 1.0049%，股份来源为股权激励计划归属；副总经理陈素勤女士直接持 有公司股份 519,500 股，占公司总股本的 0.1131%，股份来源为股权激励计划归 属；副总经理 Qingbei Zeng 先生直接持有公司股份 340,000 股，占公司总股本的 0.0740%，股份来源为股权激励计划归属；副总经理 Honchung Tsui 先生直接持 有公司股份 340,000 股，占公司总股本的 0.0740%，股份来源为股权激励计划归 属；首席财务官、董事会秘书吕洪斌先生直接持有公司股份 76,416 股，占公司 总股本的 0.0166%，股份来源为股权激励计划归属及二级市场增持。 减持计划的实施结果情况 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者 ...

证券代码：688192 证券简称：迪哲医药 公告编号：2025-47 迪哲（江苏）医药股份有限公司 自愿披露关于舒沃哲®全球注册临床研究入选 2025 年世界肺 癌大会（WCLC）口头报告及多项非小细胞 肺癌领域研究入选的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 迪哲（江苏）医药股份有限公司（以下简称"公司"）将在 2025 年 9 月 6 日至 9 日于西班牙巴塞罗那举行的 2025 年世界肺癌大会（WCLC）上，公布其 自主研发的新型肺癌靶向药舒沃哲®（ZEGFROVY®，通用名：舒沃替尼片）和 高选择性 JAK1 抑制剂高瑞哲®（通用名：戈利昔替尼胶囊）在非小细胞肺癌中 的多项最新研究成果。其中，舒沃哲®国际多中心注册临床研究"悟空 1B" （WU-KONG1B）最新数据入选口头报告。 一、关于舒沃哲®国际多中心注册临床研究 舒沃哲®国际多中心注册临床研究"悟空 1B"（WU-KONG1B）旨在评估舒 沃哲®二/后线治疗表皮生长因子受体（EGFR）20 号外显子插入突变（Exon20ins） 非小细胞肺癌（ ...

Core Viewpoint - The company, Dige Medical, will present its newly developed targeted lung cancer drugs, ZEGFROVY (generic name: Shuwotini tablets) and a highly selective JAK1 inhibitor, Goliqitini capsules, at the 2025 World Lung Cancer Conference (WCLC) in Barcelona, Spain, from September 6 to 9, 2025 [1] Summary by Relevant Categories - **Product Development** - Dige Medical is set to showcase multiple latest research results on its innovative lung cancer therapies at an upcoming international conference [1] - The international multicenter registration clinical study "Wu-Kong1B" for ZEGFROVY has had its latest data selected for an oral presentation [1]

Core Viewpoint - The report highlights a positive performance in the pharmaceutical sector, particularly in the innovative drug industry, driven by ongoing licensing agreements and supportive domestic policies [3]. Fund Performance - The fund reported a profit of 26.97 million yuan in Q2 2025, with a weighted average profit per fund share of 0.0627 yuan [2]. - The fund's net asset value (NAV) growth rate for Q2 was 7.62%, and the fund size reached 375 million yuan by the end of Q2 [2][16]. - As of July 18, the fund's unit NAV was 0.96 yuan [2]. - The fund's performance over the past three months showed a NAV growth rate of 14.74%, ranking 112 out of 138 comparable funds [4]. - Over the past six months, the fund's NAV growth rate was 25.40%, ranking 100 out of 138 [4]. - The one-year NAV growth rate was 24.99%, also ranking 100 out of 133 [4]. - The three-year NAV growth rate was 4.99%, ranking 46 out of 107 [4]. Investment Strategy - The fund manager expressed optimism about the innovative drug sector, indicating a shift from a general revaluation phase to a stage where actual performance and partnerships will be tested [3]. - The strategy includes a "barbell" approach, focusing on high-probability or high-return innovative drug companies [3]. - The fund is also looking at sectors with strong performance, such as orthopedics and upstream innovative drugs, while making early allocations in improving sectors like medical devices [3]. - New technologies like AI and brain-computer interfaces are expected to transform the healthcare system, although short-term financial impacts on related companies may be limited [3]. Risk and Return Metrics - The fund's three-year Sharpe ratio was 0.1406, ranking 41 out of 105 comparable funds [9]. - The maximum drawdown over the past three years was 29.8%, ranking 97 out of 106 [11]. - The fund's average stock position over the past three years was 85.43%, slightly below the comparable average of 86.95% [14].

Core Viewpoint - The approval of the innovative drug Shuwozhe by Dize Pharmaceutical for treating EGFR exon20ins NSCLC marks a significant advancement in addressing a challenging target that has been difficult to treat with existing therapies [1][2]. Group 1: Drug Approval and Market Position - Dize Pharmaceutical's drug Shuwozhe has received accelerated approval from the FDA for use in adult patients with locally advanced or metastatic NSCLC harboring EGFR exon20ins mutations [1][2]. - Shuwozhe is recognized as the first and only small molecule targeted therapy for EGFR exon20ins NSCLC globally, having previously received approval in China [2]. Group 2: Clinical Research and Development - The approval was based on data from the international multicenter clinical study "Wukong 1B," which demonstrated the efficacy and safety of Shuwozhe in patients with EGFR exon20ins NSCLC [3]. - The drug's submission process involved extensive communication with the FDA, ensuring alignment on data and documentation requirements, and achieving a "zero deficiency" status during the independent registration process [3]. Group 3: Strategic Vision and Internationalization - Dize Pharmaceutical aims for global market competitiveness through solid scientific research and early international multicenter clinical trials [4]. - The company emphasizes the importance of maintaining a clear strategic focus and adaptability in the face of unforeseen events during international clinical trials [4]. - Dize Pharmaceutical's strategy includes direct market entry for its drugs, contrasting with other domestic companies that often rely on external partners for commercialization [4][5].

Core Viewpoint - The company, Dize Pharmaceutical, emphasizes its commitment to "source innovation" and "global competition," successfully validating its capability in international multi-center clinical research and overseas approval for innovative drugs [1][3]. Group 1: Company Overview - Dize Pharmaceutical focuses on innovative therapies for malignant tumors and immune diseases, aiming to address unmet clinical needs globally [1][2]. - The company has established seven globally competitive product pipelines, with two leading products, Shuwozhe and Huiruozhe, having reached key clinical trial endpoints and received approvals in China and the U.S. [1][3]. Group 2: Product Development and Clinical Trials - Shuwozhe was included in the NCCN guidelines for treating EGFR exon20ins non-small cell lung cancer (NSCLC) and received FDA approval, filling a significant treatment gap [2][3]. - The company has conducted over 200 clinical trials across more than 20 countries, with ongoing global Phase III clinical studies for Shuwozhe and DZD8586 [4][5]. Group 3: Financial Performance - In 2024, Dize Pharmaceutical reported a revenue of 360 million yuan, a 294% increase year-on-year, and for Q1 2025, revenue reached 160 million yuan, reflecting a 96% growth [6]. Group 4: Strategic Insights - The company advocates for early international multi-center clinical trials to validate drugs and gain international recognition, suggesting that this approach is crucial for domestic pharmaceutical companies aiming for global markets [4][5]. - Dize Pharmaceutical's core strategy involves developing drugs for global competition while establishing technological barriers in familiar and advantageous fields [5][6].

Group 1 - The Shanghai Stock Exchange has released the "Self-Regulatory Supervision Guidelines for Companies Listed on the Sci-Tech Innovation Board No. 5 - Sci-Tech Growth Tier" [1] - The reform does not impose additional listing thresholds for unprofitable companies entering the Sci-Tech Growth Tier, allowing 32 existing unprofitable companies to enter immediately upon the guideline's implementation [1] - Newly registered unprofitable companies will enter the Sci-Tech Growth Tier from the date of their listing [1] Group 2 - Investors participating in the subscription and trading of newly registered stocks in the Sci-Tech Growth Tier must sign a "Risk Disclosure Statement for the Sci-Tech Growth Tier" [2] - The 32 existing companies that have not yet removed the "U" designation include: Zejing Pharmaceutical, Junshi Biosciences, Frontier Biotech, Qingyun Technology, Hehui Optoelectronics, Jingjin Electric, BeiGene, Dize Pharmaceutical, Maiwei Biotech, Aojie Technology, Yuhong Pharmaceutical, Shouyao Holdings, Haichuang Pharmaceutical, CloudWalk Technology, Yifang Biotech, Obsidian Optics, Mengke Pharmaceutical, Nuo Cheng Jianhua, Xinke Mobile, Xinghuan Technology, Yutai Micro, Yuntian Lifa, Tianzhihang, Qi Anxin, Hanwujin, Yihua Tong, Aifute, Huizhiwei, Xinlian Integrated, Zhixiang Jintai, Shengke Communication, and Zhongjuxin [2]

Core Viewpoint - Dize Pharmaceutical's Shuwotai (舒沃替尼片) has been included in the NCCN guidelines for non-small cell lung cancer (NSCLC), marking it as the only small molecule targeted therapy for EGFR exon 20 insertion mutations globally [1][2] Group 1: Product Development and Approval - Shuwotai has received priority review and approval from the FDA, highlighting its significance in the treatment landscape for NSCLC patients with specific mutations [1] - The drug represents a breakthrough in addressing the challenges of drug development, providing a safe and effective targeted treatment option for patients [1] Group 2: Research and Validation - The successful transition from domestic clinical research ("Wukong 6") to international multi-center studies ("Wukong 1B") signifies a comprehensive validation of a Chinese-developed innovative drug on a global scale [1] - The research led by Professor Wang Mengzhao from Peking Union Medical College Hospital emphasizes the drug's potential impact on patient care [1] Group 3: Company Vision and Investment Perspective - Dize Pharmaceutical's founder, Zhang Xiaolin, emphasizes the company's commitment to "source innovation" and "global competition," establishing a strong foundation for its drug development capabilities [2] - Investment perspectives highlight the importance of teams that combine scientific expertise with entrepreneurial spirit, suggesting a strong investment rationale for Dize Pharmaceutical [2] - The success of Shuwotai is seen as a demonstration of China's capabilities in the global pharmaceutical market, potentially paving the way for more Chinese original molecules and companies to gain international recognition [2]

Core Insights - The approval of ZEGFROVY (suwotrectin) by the FDA and its inclusion in the NCCN guidelines marks a significant milestone for the company and the industry, establishing it as the first and only targeted therapy for EGFR exon20ins NSCLC globally [1][2] - The successful development of ZEGFROVY demonstrates the potential for Chinese biotech firms to innovate and compete on a global scale, shifting from technology output to value output [2] Company Developments - ZEGFROVY is recognized as the first innovative drug developed independently in China to receive approval in the U.S., highlighting the company's capability in full lifecycle drug development [1] - The company emphasizes its commitment to "source innovation" and global competition, which has been validated through the successful launch of ZEGFROVY [1][2] Industry Implications - The success of ZEGFROVY encourages other companies to plan international clinical trials and global registration strategies from the early stages of drug development [2] - There is a call for a clear tiered evaluation system for innovative drugs at the national level, which would provide institutional incentives for source innovation and guide the industry towards high-quality development [2]